Teva Pharmaceutical Industries Ltd

Most Recent

  • uploads///Graph
    Miscellaneous

    Teva Can Benefit by Acquiring Allergan Generics

    The combined Teva–Allergan generics entity should have approximately 320 Abbreviated New Drug Applications (or ANDAs), including 110 first-to-file ANDAs (or FTF) in the US.

    By Margaret Patrick
  • uploads///teva loss
    Company & Industry Overviews

    Teva Pharmaceutical: Earnings Trends and Recent Developments

    Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Teva Pharmaceutical in 2017

    Following the completion of its acquisition of Allergan’s Actavis Generics business on August 2, 2016, Teva Pharmaceutical plans to focus on realizing the deal’s synergies in 2017.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Why the Majority of Analysts Deem Novartis a ‘Buy’

    Novartis met Wall Street analysts’ estimates for EPS (earnings per share) in 4Q16, reporting EPS of $1.12 as estimated but missing revenue estimates.

    By Mike Benson
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Teva Stock Has Risen Significantly since November Lows: What’s Next?

    On January 5, 2018, Teva Pharmaceuticals (TEVA) closed at $19.2 per share, which was ~77% higher than its 52-week low of $10.8 reported on November 2, 2017.

    By Sarah Collins
  • uploads///pharma challenges Japan
    Company & Industry Overviews

    What Are the Challenges for the Pharmaceutical Industry in Japan?

    Japan is the second-largest individual pharmaceutical market in the world. It accounts for less than 10% of the total global pharma market.

    By Jillian Dabney
  • uploads///holdings in valeant
    Company & Industry Overviews

    What Does Valeant’s Institutional Ownership Look Like?

    Of its total outstanding shares, Valeant Pharmaceuticals’ (VRX) institutional ownership stood at 69.2%.

    By Jillian Dabney
  • uploads///recommendation
    Company & Industry Overviews

    Berkshire Hathaway Increased Its Stake in Teva Again

    Teva stock has gained ~27.0% year-to-date on the back of the positive news that included product launches and study data.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    This Space Presents a Market Opportunity for Valeant

    In Valeant’s 2Q16 earnings, Xifaxan reported a year-over-year (or YoY) increase in monthly prescriptions of about 28.0%.

    By Margaret Patrick
  • uploads///valuation
    Company & Industry Overviews

    Investor Insights: Teva Pharmaceutical’s Valuation Multiples

    On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Teva Is Expected to See a Fall in Its Profit Margins in 2017

    Teva Pharmaceutical (TEVA) expects its 2017 non-generally accepted accounting principles (non-GAAP) earnings per share (or EPS) to fall in the range of $4.9–$5.3.

    By Margaret Patrick
  • uploads///tablets _
    Earnings Report

    Teva Stock Rises on Strong 1Q18 Results, Outlook Up

    Today, Teva Pharmaceutical Industries (TEVA) released its 1Q18 earnings results for the quarter that ended on March 31.

    By Sarah Collins
  • uploads///segemnts and margins
    Company & Industry Overviews

    Yes, There Will Be Margin Erosion for Valeant in 2017

    Of its three businesses, Bausch & Lomb’s share in Valeant Pharmaceuticals’ (VRX) overall EBITA (earnings before interest, tax, and amortization) was 32%.

    By Jillian Dabney
  • uploads///syringe _
    Company & Industry Overviews

    Teva’s Granix Gets FDA Approval for Expanded Indication

    Today, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new presentation and indication.

    By Sarah Collins
  • uploads///sales estimates
    Company & Industry Overviews

    Competition Dynamics for Ajovy—Teva’s Migraine Drug

    Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.

    By Sarah Collins
  • uploads///featured image
    Company & Industry Overviews

    An Overview of Valeant Pharmaceuticals’ Performance in 1Q18

    Valeant Pharmaceuticals (VRX) announced that it would change its name to Bausch Health Companies, which is expected to be effective in July.

    By Daniel Collins
  • uploads///specialty products pipeline
    Company & Industry Overviews

    Non-Opioid Pain Therapy Market Opportunity for Teva

    The Trump administration proposed production cuts in some of the most abused opioid compounds by 10% next year.

    By Sarah Collins
  • uploads///pill _
    Earnings Report

    What Analysts Recommend for Mylan before Q2 2018 Earnings

    Mylan (MYL) plans to release its Q2 results on August 8. Thirteen of the 20 analysts covering the stock have given it a “buy” or “strong buy.”

    By Sarah Collins
  • uploads///AXE
    Energy & Utilities

    Millennium Management adds new position in Anixter International

    For 1Q14, Anixter’s results beat on earnings, but missed on revenue.

    By Samantha Nielson
  • uploads///Graph
    Company & Industry Overviews

    Teva’s Share of the US Generics Market Could Boost Its Stock

    Teva Pharmaceutical Industries accounts for 18% of the US generic drug market. This share is significantly higher than those of Mylan, Novartis, and Pfizer.

    By Margaret Patrick
  • uploads///pill _
    Company & Industry Overviews

    FDA Rejects Mylan’s Generic Advair Again, Stock Falls

    On June 13, Mylan (MYL) announced that the FDA did not approve its generic version of GlaxoSmithKline’s (GSK) Advair Diskus, an asthma drug and inhaler combination.

    By Sarah Collins
  • uploads///growth of generics
    Company & Industry Overviews

    Rx for Growth? Why Generic Drugs Are Gaining Traction

    Rx for Growth? The trillion-dollar pharmaceutical industry has historically been dominated by a few major companies that create and supply the most important branded prescriptions on the market. Recent trends, however, point to the growth of the newest pharma blockbusters: generics. Today, approximately 60% of Americans take prescription drugs;[1. “Trends in Prescription Drug Use Among […]

    By VanEck
  • uploads///generics product update
    Company & Industry Overviews

    A Look at Teva’s Generic Drugs Research Pipeline

    Teva Pharmaceutical Industries has the largest generics product pipeline in the industry. It has 325 applications that are awaiting FDA approval.

    By Sarah Collins
  • uploads///inorganic growth
    Company & Industry Overviews

    Four Key Deals: Analyzing Pfizer’s Impending Growth

    Over the past year, Pfizer completed multiple acquisitions to restore its top line growth. They will offset the revenue decline and fuel Pfizer’s top line.

    By Jillian Dabney
  • uploads///otc_and_api
    Company & Industry Overviews

    Teva Pharmaceutical’s Generic Medicines Segment in 4Q17

    In 4Q17, Teva Pharmaceutical’s (TEVA) generic medicines segment reported revenues of $3.1 billion compared to $3.7 billion in 4Q16.

    By Daniel Collins
  • uploads///generics
    Earnings Report

    Inside the Double-Digit Fall for Mallinckrodt’s Specialty Generics Business in 2016

    Specialty Generics’ contribution to Mallinckrodt’s net sales fell by 18% to $1 billion in 2016. The business had a 31% share in total net sales in 2016.

    By Jillian Dabney
  • uploads///Geographic exposure
    Company & Industry Overviews

    Central Nervous System Is Key to Teva’s Specialty Medicines

    Revenues for Teva’s (TEVA) Specialty Medicines segment grew by 2.1% to $8,560 million in 2014, from $8,388 million in 2013.

    By Nicole Sario
  • uploads///COPAXONE
    Company & Industry Overviews

    Teva’s Copaxone Maintains Market Share amid Intense Competition

    In fiscal 1Q18, Teva (TEVA) reported sales of $645 million for its multiple sclerosis drug, Copaxone, a sequential decline of ~21%.

    By Sarah Collins
  • uploads///headache _
    Company & Industry Overviews

    Amarin and Teva Settle Vascepa Patent Litigation

    On May 24, Teva stock rose ~2.3%, partly triggered by the news of its litigation settlement.

    By Sarah Collins
  • uploads///Chart
    Miscellaneous

    Teva’s Respiratory Drugs Contribute 11% to Specialty Medicines

    Teva’s respiratory drugs franchise provides solutions for asthma, COPD, and allergic rhinitis. Respiratory drugs contributed nearly 11% of total revenues for Teva’s Specialty Medicines in 2014.

    By Mike Benson
  • uploads///austedo
    Company & Industry Overviews

    Teva’s Austedo Sales Continue to Gain Momentum in 2018

    In 1Q18, Teva Pharmaceutical (TEVA) reported sales of $30 million from the sales of its Austedo drug.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Akorn’s Macro-Level Challenges in the Generic Drug Segment

    Although generic drugs only account for 3% of the total healthcare costs in the US, regulators continue to be concerned about rising generic pricing.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug

    On October 17, 2016, Teva and Regeneron announced that the FDA had placed the Phase 2 study for fasinumab on clinical hold.

    By Margaret Patrick
  • uploads///ADJUSTMENTS
    Company & Industry Overviews

    What’s behind Teva’s $706 Million Impairment Charges in 1Q18?

    In 1Q18, Teva Pharmaceutical Industries (TEVA) recorded non-GAAP (generally accepted accounting principles) EPS (earnings per share) of $0.94 and net income of $954 million.

    By Sarah Collins
  • uploads///Oncology Franchise
    Company & Industry Overviews

    The Latest on TEVA’s Oncology Business

    In 1H17, Teva Pharmaceutical’s (TEVA) oncology business generated revenues of ~$550 million, or ~9% lower YoY (year-over-year).

    By Daniel Collins
  • uploads///pills _
    Company & Industry Overviews

    Teva Announces First-to-File Launch of Generic Cialis

    Yesterday, Teva Pharmaceutical Industries (TEVA) announced the exclusive FTF (first-to-file) launch of the generic Cialis1 tablets in the US.

    By Sarah Collins
  • uploads///long term debt
    Company & Industry Overviews

    Will Valeant be Able to Manage Its Huge Debt?

    With its acquisitions, Valeant’s long-term debt kept on swelling until it reached $30.2 billion at the end of 4Q15. It plans to repay $1.7 billion in 2016.

    By Jillian Dabney
  • uploads///medical _
    Earnings Report

    Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results

    Mylan (MYL) reported its Q2 earnings on August 8. On August 13, 13 of 20 surveyed firms still held a “buy” or “strong buy” rating on MYL.

    By Sarah Collins
  • uploads///RD Generic Pharma
    Macroeconomic Analysis

    Expert Q&A: What to Know Before Investing in Generic Pharma? (Part 2)

    (continued from Part 1) 4. What is the nature of the cash flows for generics companies? Stable, driven by a constant demand for prescription drugs? Or lumpy, driven by growth from drugs coming off patent? The larger companies in this sector tend to have stable, steadier cash flows due to established lineups of approved products. […]

    By VanEck
  • uploads///Generic Pharma Sales
    Macroeconomic Analysis

    Expert Q&A: What to Know Before Investing in Generic Pharma? (Part 1)

    Market Realist analysts recently conducted a Q&A with experts from VanEck on the generic pharmaceutical industry, a space that has attracted investor interest due to upside potential from brand name drugs coming off patent, cost saving pressure in the healthcare industry, and increased worldwide demand for prescription drugs (for more on these topics, please see […]

    By VanEck
  • uploads///patent cliff top
    Company & Industry Overviews

    Why the Patent Cliff Is a Key Driver of Generic Drug Growth

    Over the last several years, patent cliffs have led to steep revenue losses for traditional pharmaceuticals as well as created a gateway for smaller companies to come to market with generics.

    By VanEck
  • uploads///Bausch
    Company & Industry Overviews

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Which of Amgen’s Drugs Could Witness Muted Growth in 2016?

    Wall Street analysts have projected that Xgeva’s revenues will reach about $1.6 billion in 2016, which represents a YoY growth of about 12.3% for Amgen.

    By Margaret Patrick
  • why did kodak stock jump
    Industrials

    Is Kodak Stock Worth Your Attention Right Now?

    By Ambrish Shah
  • uploads///aerial view of various medical pills pharmaceutical
    Company & Industry Overviews

    An Easier Way to Understand the Pharma Industry

    In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

    By Sybil Prowse
  • Healthcare

    Third Point believes Amgen’s acquisitions should have done more

    Faced with expiring patents and increasing competition for its blockbuster drugs, Amgen acquired Onyx to benefit from the latter’s innovative oncology portfolio and pipeline.

    By Samantha Nielson
  • uploads///Ignyta risks
    Company & Industry Overviews

    Ignyta and Its Key Risks in 2018

    In October 2017, Ignyta (RXDX) raised $150 million by issuing 10 million shares of its common stock.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    What Are Mylan’s Key Growth Drivers in Fiscal 2019?

    In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%.

    By Margaret Patrick
  • uploads///AdobeStock_
    Healthcare

    Pfizer and Mylan: Is Mega-Merger on the Horizon?

    The Wall Street Journal first announced the probable merger of Pfizer’s (PFE) off-patent business with Mylan (MYL) on July 27.

    By Margaret Patrick
  • uploads///capsule _
    Company & Industry Overviews

    What’s Pulling Down Teva Pharmaceutical Stock?

    In the coming months, Teva Pharmaceutical will be facing a federal court trial in Cleveland related to multiple opioid abuse cases.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Pharmaceutical Is Facing These Challenges in 2019

    On its first-quarter earnings conference call, Teva Pharmaceutical (TEVA) reaffirmed its 2019 global sales guidance of $1.30 billion for its Copaxone franchise.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Ajovy and Austedo: Teva Pharmaceutical’s Growth Strategy

    On April 2, Teva Pharmaceutical issued a press release announcing the European Union’s approval of its monthly and quarterly dosages of Ajovy for preventing migraines.

    By Margaret Patrick
  • uploads///laboratory _
    Company & Industry Overviews

    What Are Analysts Recommending for TEVA and ENDP in May?

    On May 13, Teva Pharmaceutical (TEVA) closed at $12.23, 14.83% lower than its previous day’s close.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Bausch Health’s Key Growth Drivers in 2019?

    In its fourth-quarter earnings conference call, Bausch Health Companies (BHC) has highlighted its Bausch + Lomb/International segment and Salix segment as the key growth drivers for the company in fiscal 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?

    On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.

    By Margaret Patrick
  • uploads///hypertension _
    Company & Industry Overviews

    What Analysts Are Recommending for Teva Pharmaceutical This Month

    On February 15, Teva Pharmaceutical (TEVA) closed at $17.98, 4.05% higher than its previous closing price.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Pharmaceutical or Mylan: Which Has the Better Debt Profile?

    In the first nine months of 2018, Teva Pharmaceutical (TEVA) reduced its net debt level by $3.9 billion to $27.6 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Pharmaceutical or Mylan: Which Is More Cost Optimal?

    According to Teva’s 37th Annual J.P. Morgan Healthcare Conference transcript, it reduced its spending base by $1.8 billion in the first nine months of 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva or Mylan: Whose Earnings Are Growing Faster?

    In its third-quarter earnings investor presentation, Teva Pharmaceutical forecast 2018 non-GAAP EPS of $2.80–$2.95.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva or Mylan: Who Has the More Promising Revenue Trajectory?

    In its third-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) forecast total 2018 revenue in the range of $18.6 billion–$19.0 billion.

    By Margaret Patrick
  • uploads///Teva pharma
    Company & Industry Overviews

    A Financial Overview of Teva Pharmaceutical in December

    In the first nine months of 2018, Teva Pharmaceutical’s net revenue fell 16% YoY (year-over-year) to $14.3 billion from $17.0 billion.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Teva Pharmaceutical Stock Rose More than ~8% on December 26

    On December 26, Teva Pharmaceutical (TEVA) stock closed at $15.82, a rise of ~8.43% from its close of $14.59 on December 24.

    By Daniel Collins
  • uploads///pills _
    Company & Industry Overviews

    Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval

    On December 5, Bausch + Lomb announced that the FDA approved its Ultra multifocal contact lenses for patients with astigmatism.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Ajovy Is a New Growth Driver for Teva Pharmaceutical

    On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    A Look at Celgene’s Revlimid Label Expansion Initiatives in 2018

    On October 23, 2018, Celgene issued a press release announcing favorable results from open-label Phase 2/3 trial, ECOG E3A06, evaluating Revlimid in the smoldering multiple myeloma (or MM) indication.

    By Margaret Patrick
  • uploads///bausch
    Company & Industry Overviews

    How Bausch Health’s Financials Look in November

    Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.

    By Daniel Collins
  • uploads///Xyrem
    Company & Industry Overviews

    Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?

    Jazz Pharmaceuticals’ Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    What Are Pfizer’s Revenue Drivers?

    Pfizer reported revenues of $13.5 billion during the second quarter—4% growth YoY compared to $12.9 million during the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Novartis’s Sandoz Business Has Been Performing Recently

    Sandoz, Novartis’s (NVS) generics business, is a market leader in differentiated generics.

    By Mike Benson
  • uploads///NBIX
    Company & Industry Overviews

    Analysts Are Mostly Positive on Neurocrine Biosciences

    On October 4, Neurocrine Biosciences (NBIX) stock closed at $114.58, which is an ~3.79% decline from its October 3 close of $119.09.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    GW Pharmaceuticals: Recommendations and Market Capitalization

    Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018

    Five analysts are currently tracking GlaxoSmithKline ADR. One analyst recommends a “strong buy,” and four analysts recommend a “hold.”

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline’s Revenue Was Flat in Second Quarter

    GlaxoSmithKline (GSK) reported revenues of 7.3 billion pounds during the second quarter of 2018.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Novartis Reports Growth in Q2 2018 Earnings

    Novartis (NVS) released its Q2 2018 earnings on July 18 and surpassed Wall Street analysts’ estimates for revenues and EPS.

    By Mike Benson
  • uploads///medicine _
    Company & Industry Overviews

    Analyst Recommendations for Valeant Pharmaceuticals in July

    In July, the FDA accepted Bausch + Lomb’s NDA (New Drug Application) for sub-micron loteprednol etabonate.

    By Daniel Collins
  • uploads///tablets _
    Company & Industry Overviews

    Analyst Recommendations for Teva Pharmaceutical in July

    As of July 6, according to a recent Reuters survey, 28 analysts are tracking TEVA stock. Six of them have rated it a “buy” or “strong buy.”

    By Sarah Collins
  • uploads///Nplate
    Company & Industry Overviews

    How Amgen’s Nplate, Vectibix, and Neupogen Performed in 1Q18

    In 1Q18, Amgen’s (AMGN) Nplate revenue grew 16% YoY (year-over-year) to $179 million from $154 million, primarily driven by unit demand.

    By Daniel Collins
  • uploads///Xolair
    Company & Industry Overviews

    How Is Novartis’s Xolair Positioned after 4Q17?

    In 4Q17, Novartis’s (NVS) Xolair generated revenues of $247 million, which reflected ~14% growth on a year-over-year (or YoY) basis and ~1% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///specialty assets
    Company & Industry Overviews

    Will Teva’s Fremanezumab Be Delayed due to Troubles at Celltrion?

    Teva Pharmaceutical (TEVA) has a number of key specialty assets that are touted as key long-term growth drivers for the company.

    By Sarah Collins
  • uploads/// NON GAAP ADJUSTMENTS
    Company & Industry Overviews

    US Generics Market Consolidation Continues to Affect Teva

    In 4Q17, Teva experienced a price erosion of ~13% in its generics business.

    By Sarah Collins
  • uploads///solodyn
    Company & Industry Overviews

    Teva’s Recent Launch of Generic Solodyn: What You Need to Know

    On February 20, 2018, Teva Pharmaceutical announced the US launch of the generic version of Solodyn Extended Release tablets in two strengths.

    By Sarah Collins
  • uploads///valeants top  drugs
    Company & Industry Overviews

    How the Market Reacted to Teva’s Pricing of Its Generic Syprine

    On February 9, 2018, Teva Pharmaceuticals (TEVA) announced the US launch of its generic version of 250 mg Syprine capsules.

    By Sarah Collins
  • uploads/// MILESTONES
    Company & Industry Overviews

    Teva Terminates TV-45070 Development Agreement with Xenon

    On March 7, Teva and Xenon entered into a mutual agreement to terminate the collaborative development and license agreement they entered into in 2012.

    By Sarah Collins
  • uploads///
    Company & Industry Overviews

    Is the Amazon–Walmart Rivalry About to Spill Over into Israel?

    The retail rivalry between Amazon (AMZN) and Walmart (WMT) could spill over into Israel.

    By Ruchi Gupta
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Recommendations for Pfizer in March 2018

    Pfizer (PFE) surpassed Wall Street analysts’ consensus estimate for EPS (earnings per share) in 4Q17, reporting EPS of $0.62 compared to the estimate of $0.56.

    By Mike Benson
  • uploads///Respiratory
    Company & Industry Overviews

    Behind Merck’s Diversified Brands: A Post-4Q17 Update

    In 4Q17, Merck’s Singulair reported revenues of $182 million which represents a ~135% decline on a YoY basis and a 13% rise on a QoQ basis.

    By Daniel Collins
  • uploads///Bridion and Primaxin
    Company & Industry Overviews

    How Merck’s Bridion and Primaxin Performed in 2017

    In 4Q17, Merck’s (MRK) Bridion reported revenues of $209 million, which reflected a ~50% rise on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Innovative Medicines Business in 4Q17

    Overall, the innovative medicines business accounted for ~67.8% of Novartis’s total revenues.

    By Mike Benson
  • uploads///Cardiovascular
    Company & Industry Overviews

    How Merck’s Cardiovascular Segment Performed in 4Q17 and 2017

    In 4Q17, Merck’s Zetia reported revenues of $323 million, which was ~44% lower on a year-over-year basis and a 1% rise on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Performance of Sanofi’s Business Segments in 4Q17

    Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17 for 8.7% growth in operating revenues compared to its 4Q16 revenues.

    By Mike Benson
  • uploads///Consumer
    Company & Industry Overviews

    JNJ’s Consumer Products: OTC, Women’s Health, and Wound Care

    In 4Q17, JNJ’s Women’s Health segment generated revenues of $262.0 million, which is an ~1.0% decline on a YoY basis.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    GlaxoSmithKline’s Pharmaceuticals Business in 4Q17

    GlaxoSmithKline’s (GSK) Europe market reported ~1.0% growth in revenues to ~1.0 billion pounds in 4Q17.

    By Mike Benson
  • uploads///debt maturities
    Company & Industry Overviews

    How Wall Street Reacted to Berkshire Hathaway Investment in Teva

    Teva Pharmaceuticals stock rose ~10.5% during the morning of February 15, 2018, before closing at a rise of ~7.7% on the day.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q17 Earnings: Sandoz Business

    Sandoz reported a decline of 4.0% in operating revenues, offset by a 4.0% positive impact of foreign exchange.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Trelegy Ellipta May Emerge as Major Growth Driver for GlaxoSmithKline

    Trelegy Ellipta could enable GlaxoSmithKline to compete aggressively with other respiratory players such as Novartis (NVS).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Anoro Ellipta May Boost GlaxoSmithKline’s Respiratory Franchise Revenues

    Anoro Elipta earned revenues of close to 233 million pounds in the first nine months of 2017, which is 77% year-over-year (or YoY) growth on a reported basis and 63% YoY growth on a constant exchange rate (or CER) basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    GlaxoSmithKline Is Focused on Maintaining Leadership in This Segment

    To maintain its leadership in the chronic obstructive pulmonary disease (or COPD) segment, GlaxoSmithKline (GSK) has focused on shifting patients away from LAMA monotherapy to its LAMA/LABA bronchodilators.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    GlaxoSmithKline Has Developed a Broad Respiratory Portfolio

    In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 1.6 billion pounds from the sale of its respiratory products, which is year-over-year (or YoY) growth of 1% on a reported basis.

    By Margaret Patrick
  • uploads///Sandoz
    Company & Industry Overviews

    How Is Novartis’s Subsidiary Sandoz Positioned for 2018?

    In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) subsidiary Sandoz generated revenues of $2.4 billion, $2.5 billion, and $2.6 billion, respectively.

    By Daniel Collins
  • uploads///Chart  Inno Medicines
    Earnings Report

    Behind Novartis’s 4Q17 Estimates: Innovative Medicines

    The Innovative Medicines segment is expected to report growth in operating revenues for 4Q17.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.